Immunoprecise Antibodies - 股票

Immunoprecise Antibodies 资产回报率 2024

Immunoprecise Antibodies 资产回报率

-0.34

股票代码

IPA

ISIN

CA45257F2008

WKN

A2QJEC

在2024年,Immunoprecise Antibodies的总资产收益率 (ROA)为-0.34,较上一年的-0.18 ROA增长了91.3%

Immunoprecise Antibodies Aktienanalyse

Immunoprecise Antibodies在做什么?

Immunoprecise Antibodies Ltd is a leading company in the development of antibodies and antibody-based solutions for the pharmaceutical and biotech industry. The company was founded in 2015 as a spin-off from the University of Victoria in Canada and has since experienced rapid growth, expanding into other countries such as the USA, Europe, and Asia. The company's unique business model is based on three pillars: providing innovative research services tailored to the needs of the pharmaceutical and biotech industry, offering a broad portfolio of antibody products for research and diagnostics, and developing a pipeline of new therapeutics currently undergoing clinical trials. The core business of Immunoprecise Antibodies Ltd is the manufacturing of antibodies and antibody-based solutions for research and diagnostics. The company offers a range of innovative services, including antibody engineering, production and purification, and characterization. The research services are provided by an experienced team of scientists and experts in the field of antibody research who work closely with customers to meet their specific needs. In addition, the company has a wide range of antibody products available for various applications in research and diagnostics, including protein quantification, immunohistochemistry, cancer antigen detection, influenza diagnostics, and many others. Immunoprecise Antibodies Ltd has also developed a pipeline of new therapeutics, including antibodies against cancer, inflammation, and infectious diseases, which are currently undergoing clinical trials. The company collaborates closely with leading pharmaceutical and biotech companies to advance the latest developments in this field. To enable better focus and specialization, Immunoprecise Antibodies Ltd is divided into six divisions: humanization/antibody engineering, antibody production, antibody characterization, immunohistochemistry, therapeutics development, and process development. These divisions are strategically designed to cover the needs of customers and facilitate an effective supply chain for antibody production and development. Immunoprecise Antibodies Ltd is a young and dynamic company with a strong focus on innovation and customer satisfaction. It has earned an excellent reputation in the industry and is regarded as a valuable partner for antibody research and development by leading pharmaceutical and biotech companies. The company's goal is to remain a key player in the field of antibody research and continue developing innovative solutions for the pharmaceutical and biotech industry. Immunoprecise Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

资产回报率的详细信息

Immunoprecise Antibodies的资本回报率(ROA)理解

Immunoprecise Antibodies的资本回报率(ROA)是一个关键指标,用于衡量公司相对于总资产的盈利能力。它通过将净利润除以总资产来计算。较高的ROA表明公司有效利用资产获取收益,反映了管理效率和财务健康状况。

年度对比

比较Immunoprecise Antibodies的年度ROA能提供关于公司运营效率和资产使用趋势的洞察。ROA的增加显示了改进的资产效率和盈利能力,而ROA的下降可能表明存在运营或财务挑战。

对投资的影响

投资者视Immunoprecise Antibodies的ROA为评估公司盈利能力和效率的关键指标。较高的ROA意味着公司有效地使用其资产以获取收益,这使其可能成为一个吸引人的投资目标。

解读ROA波动

Immunoprecise Antibodies的ROA波动可能是由于净利润、资产收购或运营效率的变化。分析这些波动有助于评估公司的财务表现,管理效率和战略财务定位。

关于Immunoprecise Antibodies股票的常见问题

Immunoprecise Antibodies今年的资产回报率(ROA)是多少?

Immunoprecise Antibodies今年的资产回报率(ROA)为-0.34 undefined。

Immunoprecise Antibodies去年的ROA有多高?

Immunoprecise Antibodies的ROA与去年相比了91.3%。

Immunoprecise Antibodies的投资者面临高ROA的后果是什么?

对于Immunoprecise Antibodies的投资者来说,高ROA是有利的,因为这表明公司有效地利用了其资产并获取了良好的收益。

Immunoprecise Antibodies的投资者低ROA会有什么后果?

对于Immunoprecise Antibodies的投资者来说,较低的ROA可能不利,因为这表明公司使用其资产的效率不高,可能会获得较低的利润。

Immunoprecise Antibodies的ROA提升对公司有何影响?

ROA的提升Immunoprecise Antibodies可能是资产利用效率提高和盈利能力增强的指标。

Immunoprecise Antibodies的ROA降低会对公司产生什么影响?

ROA下降Immunoprecise Antibodies可能是资产利用效率下降和盈利能力降低的指标。

Immunoprecise Antibodies的ROA可能受哪些因素影响?

影响Immunoprecise Antibodies的ROA的一些因素包括营业额、运营成本、资产结构和行业平均水平。

为什么Immunoprecise Antibodies的ROA对投资者来说很重要?

Immunoprecise Antibodies的ROA对投资者来说非常重要,因为它是衡量公司盈利能力和资产使用效率的指标。这可以向投资者提供信息,说明公司如何有效利用其资源来创造利润。

Immunoprecise Antibodies可以采取哪些战略措施来提高ROA?

为了提高Immunoprecise Antibodies的资产收益率(ROA),他们可以采取的措施包括节省成本、提高销售额、优化资产结构以及多样化业务活动。重要的是,公司需要对其财务状况进行深入审查,以确定最佳的战略措施来提高资产收益率。

Immunoprecise Antibodies支付多少股息?

在过去的12个月中,Immunoprecise Antibodies支付了 的股息。这相当于大约的股息收益率。在未来的12个月内,Immunoprecise Antibodies预计将支付0 CAD的股息。

Immunoprecise Antibodies的股息收益率有多高?

Immunoprecise Antibodies当前的股息收益率为。

Immunoprecise Antibodies什么时候支付股息?

Immunoprecise Antibodies按季度支付股息。这些股息将在月份分发。

Immunoprecise Antibodies的股息有多安全?

Immunoprecise Antibodies 在过去0年里每年都支付了股息。

Immunoprecise Antibodies的股息有多高?

预计未来12个月的股息将达到0 CAD。这相当于0 %的股息收益率。

Immunoprecise Antibodies位于哪个行业?

Immunoprecise Antibodies 被分配到“健康”板块。

Wann musste ich die Aktien von Immunoprecise Antibodies kaufen, um die vorherige Dividende zu erhalten?

要获得Immunoprecise Antibodies在支付的0 CAD的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Immunoprecise Antibodies最后一次支付股息是什么时候?

上一次股息发放日期为。

Immunoprecise Antibodies在2023年的股息是多少?

在2023年,Immunoprecise Antibodies 分配了0 CAD作为股息。

Immunoprecise Antibodies 的股息是以哪种货币支付的?

Immunoprecise Antibodies的股息将以CAD的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Andere Kennzahlen von Immunoprecise Antibodies

我们对Immunoprecise Antibodies 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Immunoprecise Antibodies 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: